2025年接受透析治疗患者的继发性甲状旁腺功能亢进 - Suppr

Secondary hyperparathyroidism in patients on dialysis therapy in 2025.

作者信息

Drüeke Tilman B

机构信息

Institut National de la Santé et de la Recherche Médicale (Inserm), Centre de Recherche en Epidémiologie et Santé des Populations (CESP), Villejuif, France.

Paris-Saclay University (UPS), Gifsur-Yvette, France.

出版信息

J Bras Nefrol. 2025 Apr-Jun;47(2):e2025E006. doi: 10.1590/2175-8239-JBN-2025-E006en.

DOI:10.1590/2175-8239-JBN-2025-E006en

PMID:40277429

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12043330/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8de4/12043330/1834c58f5c1b/2175-8239-jbn-47-2-e2025E006-gf01.jpg

相似文献

Secondary hyperparathyroidism in patients on dialysis therapy in 2025.2025年接受透析治疗患者的继发性甲状旁腺功能亢进

J Bras Nefrol. 2025 Apr-Jun;47(2):e2025E006. doi: 10.1590/2175-8239-JBN-2025-E006en.

1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.1α(OH)D3 一α-羟基胆钙化醇——一种活性维生素 D 类似物。关于慢性透析的尿毒症患者继发性甲状旁腺功能亢进症预防和治疗的临床研究。

Dan Med Bull. 2008 Nov;55(4):186-210.

Comparison of Paricalcitol and Calcitriol in Dialysis Patients With Secondary Hyperparathyroidism: A Meta-Analysis of Randomized Controlled Studies.帕立骨化醇与骨化三醇治疗透析患者继发性甲状旁腺功能亢进的比较：一项随机对照研究的荟萃分析

Ther Apher Dial. 2019 Feb;23(1):73-79. doi: 10.1111/1744-9987.12760. Epub 2018 Oct 16.

Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients.血清成纤维细胞生长因子-23水平可预测透析患者未来的难治性甲状旁腺功能亢进。

Kidney Int. 2005 Mar;67(3):1171-8. doi: 10.1111/j.1523-1755.2005.00184.x.

Increasing rates of parathyroidectomy to treat secondary hyperparathyroidism in dialysis patients with Medicare coverage.在有医疗保险覆盖的透析患者中，甲状旁腺切除术治疗继发性甲状旁腺功能亢进症的比例不断增加。

Surgery. 2022 Jul;172(1):118-126. doi: 10.1016/j.surg.2022.02.005. Epub 2022 Mar 21.

Effect of cinacalcet treatment on vascular arterial stiffness among peritoneal dialysis patients with secondary hyperparathyroidism.西那卡塞治疗对继发性甲状旁腺功能亢进腹膜透析患者血管动脉僵硬度的影响。

Nephrology (Carlton). 2014 Jun;19(6):339-44. doi: 10.1111/nep.12223.

Secondary hyperparathyroidism in patients on maintenance hemodialysis: study of the N and C-terminal parathyroid hormones.维持性血液透析患者的继发性甲状旁腺功能亢进：N端和C端甲状旁腺激素的研究

Tokai J Exp Clin Med. 1983 Jul;8(3):225-8.

Calcimimetics treatment strategy for serum calcium and phosphate management in patients with secondary hyperparathyroidism undergoing dialysis: A systematic review and meta-analysis of randomized studies.二膦酸盐治疗策略对透析患者继发性甲状旁腺功能亢进症血钙、血磷管理的影响：一项随机研究的系统评价和荟萃分析。

Ther Apher Dial. 2024 Aug;28(4):557-571. doi: 10.1111/1744-9987.14125. Epub 2024 Mar 18.

Severe hyperparathyroidism in a pre-dialysis chronic kidney disease patient treated with a very low protein diet.透析前慢性肾脏病伴严重甲状旁腺功能亢进症患者接受极低蛋白饮食治疗。

J Bone Miner Metab. 2012 Mar;30(2):238-42. doi: 10.1007/s00774-011-0320-6. Epub 2011 Oct 12.

Impact of Parathyroidectomy Versus Oral Cinacalcet on Bone Mineral Density in Patients on Peritoneal Dialysis With Advanced Secondary Hyperparathyroidism: The PROCEED Pilot Randomized Trial.甲状旁腺切除术与口服西那卡塞对晚期继发性甲状旁腺功能亢进腹膜透析患者骨密度的影响：PROCEED 先导随机试验。

Am J Kidney Dis. 2024 Apr;83(4):456-466.e1. doi: 10.1053/j.ajkd.2023.10.007. Epub 2023 Nov 30.

本文引用的文献

Secondary hyperparathyroidism due to chronic kidney disease and access to clinical treatment and parathyroidectomy in Brazil: a nationwide survey.巴西慢性肾脏病所致继发性甲状旁腺功能亢进及临床治疗与甲状旁腺切除术的可及性：一项全国性调查

J Bras Nefrol. 2025 Apr-Jun;47(2):e20240158. doi: 10.1590/2175-8239-JBN-2024-0158en.

Chronic kidney disease-mineral and bone disorder: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.慢性肾脏病-矿物质和骨异常：来自改善全球肾脏病预后组织（KDIGO）争议会议的结论

Kidney Int. 2025 Mar;107(3):405-423. doi: 10.1016/j.kint.2024.11.013. Epub 2025 Jan 24.

Parathyroidectomy vs Cinacalcet Among Patients Undergoing Hemodialysis.甲状旁腺切除术与西那卡塞在血液透析患者中的比较。

J Clin Endocrinol Metab. 2022 Jun 16;107(7):2016-2025. doi: 10.1210/clinem/dgac142.

Independent effects of secondary hyperparathyroidism and hyperphosphataemia on chronic kidney disease progression and cardiovascular events: an analysis from the NEFRONA cohort.继发性甲状旁腺功能亢进和高磷血症对慢性肾脏病进展及心血管事件的独立影响：来自NEFRONA队列的分析

Nephrol Dial Transplant. 2022 Mar 25;37(4):663-672. doi: 10.1093/ndt/gfab184.

Changing bone patterns with progression of chronic kidney disease.随着慢性肾脏病的进展，骨骼模式发生变化。

Kidney Int. 2016 Feb;89(2):289-302. doi: 10.1016/j.kint.2015.12.004.

The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial.接受血液透析患者甲状旁腺功能亢进症的治疗临床病程和西那卡塞的作用：EVOLVE 试验。

J Clin Endocrinol Metab. 2013 Dec;98(12):4834-44. doi: 10.1210/jc.2013-2975. Epub 2013 Oct 9.

Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population.血清 iPTH、钙和磷与欧洲血液透析人群的死亡率风险。

Nephrol Dial Transplant. 2011 Jun;26(6):1948-55. doi: 10.1093/ndt/gfq219. Epub 2010 Apr 25.

KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).改善全球肾脏病预后组织（KDIGO）慢性肾脏病-矿物质和骨异常（CKD-MBD）诊断、评估、预防及治疗临床实践指南。

Kidney Int Suppl. 2009 Aug(113):S1-130. doi: 10.1038/ki.2009.188.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Secondary hyperparathyroidism in patients on dialysis therapy in 2025.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

本文引用的文献